Hedge fund Elliott Management and Veritas Capital, a private equity firm, are planning to buy Athenahealth for $5.7 billion. Elliott took a stake in the healthcare software-maker last year and began pressuring the company to sell itself. (CNBC)
Driver has shut down only weeks after its high-profile rollout. The app, which matched cancer patients with clinical trials, wasn’t making money quickly enough to satisfy potential investors. The San Francisco-based company let go of its 85 staffers in mid-October. (STAT)
Clinical trial results confirmed topline data showing that Amarin’s fish oil-derived prescription drug, Vascepa, could be a potential blockbuster. The treatment decreased the risk of cardiovascular events death, heart attack, and stroke by 26% compared to a placebo. Some experts raised questions regarding the placebo used, however. (STAT)
The company resulting from Takeda’s acquisition of Shire could make its debut at January’s JPMorgan conference. The U.S. and Japan have signed off on the deal; European regulators are set to announce their decision this month. (Endpoints)
AstraZeneca diabetes medicine Farxiga was found to prevent heart failure and reduce the risk of kidney problems in a broad range of patients in a clinical trial. However, the drug failed to show much progress in preventing heart attacks or strokes. (Reuters)
